Recent observations have suggested a role of neutrophil extracellular traps (NETs) in the pathophysiology of severe COVID-19. The aim of the study is to assess efficacy and safety of aerosolized DNase I to remove NETs and decrease respiratory distress in patients with COVID-19.
Study objectives: Primary objective: To compare the treatment effect of aerosolized DNase I
to that of placebo (NaCl, 0.9%) on time to cessation of oxygen therapy or discharge from
hospital in hospitalized patients with COVID-19 and respiratory dysfunction.
Secondary objectives: To compare the treatment effect of aerosolized DNase I to that of
placebo (NaCl, 0.9%) on 28-day mortality, days alive and without ventilator treatment, days
alive and without high flow nasal oxygen treatment (Optiflow), length of stay in the ICU,
days alive and outside hospital, relapse of hypoxia, days alive and without need for
supplemental oxygen, adverse reactions.
Exploratory objectives: To compare the treatment effect of aerosolized DNase I to that of
placebo (NaCl, 9%) on quantification of NETs in respiratory secretions and on the incidence
of clinical thromboembolic events.
Study design: Phase 2 open-label randomized controlled multicentre trial. The study period is
28 days from randomization. A long term follow-up on mortality and readmission will also be
collected via patient medical records/registries at day 90, day 180, and day 360 after
randomization.
Drug: aerosolized DNase
DNase
Drug: NaCl
NaCl 0.9%, isotonic saline
Inclusion Criteria:
- Age ≥18 years old
- Admitted to hospital ward or ICU
- A positive PCR test for SARS-CoV-2 from throat swab or nasopharynx
- An oxygen saturation ≤90% after maximum 15 minutes without supplemental oxygen
- Signed informed consent
Exclusion Criteria:
- Mental inability, reluctance or language difficulties that result in difficulty
understanding the meaning of study participation
- Known or suspected allergy against Pulmozyme
- Chronic obstructive pulmonary disease stage III-IV or another comparable chronic
respiratory disease
- Participation in a clinical study with an investigational product during the last 30
days
- Previous participation in this study
- Pregnancy. Women of childbearing potential must agree to use contraceptives for the
duration of the study period
- Any condition that, in the opinion of the Investigator, would place the patient at
increased risk or preclude the patient's compliance with the study
Lund ED
Lund, Sweden
Investigator: Adam Linder
adam.linder@med.lu.se
Adam Linder, MD
004646171130
adam.linder@med.lu.se
Adam Linder, MD, Principal Investigator
Region Skåne